FDA Classifies Philips Lumify Ultrasound Recall Class I

Clinical facilities must mitigate diagnostic risks as software defects on the mobile system cause scan failures.

Updated on Oct. 21, 2026 in Healthcare

Bold flat-color editorial illustration featuring a stylized geometric ultrasound probe, representing medical device safety risks. — The FDA has classified the recall of Philips Lumify ultrasound systems as Class I, citing reports of four deaths and eight serious injuries. AI Illustration. Upload story photo >

The FDA has classified the recall of Philips Lumify ultrasound systems as Class I following reports of four deaths and eight serious injuries. The recall affects various iOS and Android app versions due to critical software defects that can interrupt diagnostic procedures.

Why it matters

The Class I designation indicates that use of the device may cause serious injury or death, as system failures can force critical delays in patient diagnosis and treatment. For operators in clinical settings, this necessitates an immediate evaluation of device stability and reliance on backup equipment.

The recall involves four deaths and eight serious injuries linked to system failures, prompting the FDA to issue a Class I status. The total scope includes multiple versions of the Lumify software on both iOS and Android platforms.

The players

FDA

The federal agency responsible for protecting public health by regulating medical devices and overseeing the safety of healthcare equipment.

Philips

A multinational health technology conglomerate that manufactures diagnostic imaging systems and patient monitoring equipment.

The details

The recall addresses two distinct system failures that impede diagnostic performance. First, a software defect requires users to re-register probes in a process that demands network access, potentially blocking scanning in environments without Wi-Fi or cellular service. Second, physical USB connections between the probe and display device are prone to instability or unexpected disconnections during clinical operation.

September 24, 2026: Philips issued a notification letter to affected customers.
September 29, 2026: Date by which four deaths and eight injuries were reported.
October 9, 2026: The FDA issued an Early Alert regarding the device performance issues.
October 19, 2026: The FDA officially updated the status of the device notice to a Class I recall.

Market Landscape

This Class I recall represents the most severe regulatory action available under the FDA medical device recall classification system. It reflects the agency's strict oversight on diagnostic accuracy and the potential for device failure to disrupt critical clinical care.

Clinical operators should immediately verify the version of their Lumify software and establish manual backup procedures for diagnostic scanning. Facilities should contact the Philips Ultrasound Customer Care Solutions Center at 800-722-9377 to ensure they are registered to receive the forthcoming software update.

The takeaway

The classification underscores the high operational risk posed by software-dependent medical hardware in non-networked environments. Operators must monitor the situation for the release of the pending patch and maintain strict adherence to manufacturer communication channels.